AOD-9604 Cost in the US

Why “AOD-9604 cost” doesn’t have a clean answer

Most cost questions have a tidy answer: a list price, a self-pay price, an insurance copay. AOD-9604 doesn’t, and that gap is the most useful thing to understand before you spend a dollar.

A price only exists where there’s a legitimate supply chain to attach it to. For an FDA-approved drug, the price reflects a manufactured, tested product moving through pharmacies under prescription. For a peptide that can be lawfully compounded, the price reflects a licensed pharmacy preparing it for a specific patient. AOD-9604 in 2026 has neither. It isn’t FDA-approved, and — unlike some peptides currently working their way through review — it isn’t on the FDA’s 503A bulks list, which means a compounding pharmacy can’t lawfully prepare it even with a prescription in hand.

So when you search “AOD-9604 cost” and find numbers, you’re almost never looking at the price of a regulated medicine. You’re looking at the price of something else entirely, dressed up to look comparable. The rest of this page is about telling those things apart.

Note: This page is about money — what the numbers mean and what you’re really buying. For the legal mechanics of why no pharmacy can fill it, see how to get AOD-9604 and the AOD-9604 prescription page. For whether it works at all, see AOD-9604 for weight loss.

The numbers you’ll see online — and what they actually are

There are roughly three kinds of figure floating around for AOD-9604, and they describe three different worlds. They are not points on a single price range.

Research-only vials (the cheap headline number)

The lowest and most common figures — often a few tens of dollars for a small vial — come from “research use only” (RUO) vendors. These sites sell lyophilized powder labeled for laboratory use, not human use. That labeling isn’t a technicality. It means the product carries no assurance that what’s in the vial matches the label, no sterility validation for injection, no pharmacist oversight, and no medical evaluation of you as a patient. The “research only” disclaimer is precisely what keeps these vendors outside the system that would otherwise make them responsible for any of that.

This is the source of the impression that AOD-9604 is cheap. It is cheap — because everything that makes a medicine a medicine has been stripped out of the price.

Bundled clinic or telehealth “fat-loss” program pricing

Some wellness, anti-aging, or weight-loss clinics have historically advertised AOD-9604 inside broader programs — a monthly fee that wraps a consult, “peptide therapy,” and follow-up into one number, sometimes in the range people associate with peptide programs generally ($150–400 a month is the figure that circulates). Two cautions here. First, that bundled figure is a program price, not an AOD-9604 price; the molecule’s own share is a fraction of a bill dominated by the prescriber relationship. Second, and more important, a clinic offering to supply AOD-9604 as a compounded medicine in 2026 is operating against the regulatory reality below — the medication tier it implies doesn’t lawfully exist. A legitimate clinic price for AOD-9604 specifically is, in practical terms, not a thing you should expect to find.

A speculative “future approved price”

There isn’t one, and there’s no credible way to estimate one, because AOD-9604 is not on a path toward approval or lawful compounding (see the next section). Any number presented as “what it’ll cost once it’s legal” is guesswork attached to an event that isn’t scheduled.

Why there’s no pharmacy price for AOD-9604

This is the regulatory spine, kept brief — the access pages carry the detail.

AOD-9604 is a 16-amino-acid fragment of human growth hormone that was studied, years ago, specifically as an obesity drug. It was withdrawn from the FDA’s Category 2 compounding list in September 2024 after its nominators pulled their nominations, and it was then reviewed on the agency’s own initiative by the Pharmacy Compounding Advisory Committee in late 2024 for the obesity use. It was not advanced onto the 503A bulks list.

When a fresh round of peptide activity arrived in 2026 — twelve peptides coming off Category 2 in late April, with advisory-committee meetings scheduled for July 2026 and again before the end of February 2027 — AOD-9604 was not part of it. It isn’t among the peptides being newly reviewed, and it isn’t among those slated for the later session either.

The practical translation for cost: removal from Category 2 is not the same as being added to the bulks list. A peptide has to be on that list for a 503A pharmacy to lawfully compound it. AOD-9604 isn’t, so a prescriber could in theory write for it but no pharmacy could lawfully fill it. No fillable prescription means no legitimate dispensed price. The broader peptide landscape is genuinely in motion and not finalized — but AOD-9604 specifically is sitting off to the side of that movement, not in the middle of it.

The hidden line items: the real cost of the “cheap” option

The headline RUO price looks like a saving only because the costs haven’t disappeared — they’ve been moved off the price tag and onto you.

• Unknown content. Independent testing of gray-market peptide vials repeatedly turns up products that are underdosed, overdosed, degraded, or not the labeled compound at all. You’re paying a known price for an unknown substance, which is the opposite of a good deal.
• No evaluation. A legitimate price includes someone qualified deciding whether a therapy is appropriate for you, screening for reasons it might be unsafe. The cheap vial includes none of that, and there’s no refund on a wrong decision you weren’t helped to avoid.
• No monitoring. No baseline, no follow-up, no one tracking whether anything is going wrong. The cost of an unmonitored adverse event isn’t on the invoice, but it’s real.
• No recourse. If something is wrong with the product or with you, there’s no licensed party accountable. That’s not free; it’s a cost you absorb entirely if it lands.

When people say AOD-9604 is “way cheaper,” these four items are the difference. They are the product.

What you’d actually be buying

There’s a second, quieter cost problem that’s specific to AOD-9604: even setting aside legality and product quality, the molecule didn’t deliver in the trial that mattered. It was developed as an oral obesity drug, showed a modest early signal, and then missed its primary endpoint in the larger, longer pivotal study before development was abandoned. So a buyer is paying — whatever the number — for a compound with no demonstrated meaningful weight-loss benefit in controlled human trials, in an injectable gray-market form that was never the form studied. Cost-per-result is the metric that actually matters, and here the denominator is the problem. The evidence detail lives on AOD-9604 for weight loss and for fat loss; the point for a cost page is simply that a low price on something that doesn’t work is not value.

A fairer cost comparison: the lawful fat-loss route

If the underlying goal is fat loss rather than this specific molecule, the honest cost comparison isn’t “AOD-9604 vials vs. nothing” — it’s “AOD-9604 vs. the route that’s actually legal and actually works.”

The FDA-approved GLP-1 and dual-agonist medications (semaglutide and tirzepatide) are real, prescribable, and supported by large trials, and they’re dispensable everywhere through normal channels. They cost meaningfully more on paper than a research vial — but you’re now comparing a tested medicine with a prescriber, a pharmacy, and monitoring against an unverified powder with none of that. The relevant pricing has also shifted a lot recently, with manufacturer cash-pay programs changing what self-pay patients actually owe. Rather than restate figures that move month to month, see how to get semaglutide, how to get tirzepatide, and the dedicated semaglutide cost and tirzepatide cost breakdowns for current numbers. The point here is structural: one of these routes has a real price because it’s a real medicine; the other has a cheap price because it’s been removed from the system that would make it one.

Insurance and AOD-9604

Briefly, because people ask: US health insurance does not cover AOD-9604. It isn’t FDA-approved and has no legitimate dispensing channel, so there’s nothing for a plan to adjudicate. This is the norm for peptides generally — they’re overwhelmingly cash-pay. The one place insurance sometimes engages is the FDA-approved obesity-medication class, where some commercial plans cover GLP-1 therapy for qualifying patients (often with prior authorization and on-label restrictions). That’s another reason the lawful route can be closer in real out-of-pocket cost than the sticker prices suggest, and another reason to price it out properly before assuming the vial is cheaper.

Bottom line

The reason “AOD-9604 cost” returns such low numbers is not that it’s a bargain — it’s that the cheap figures are research-vial prices for an unregulated product with no prescriber, no verified content, no monitoring, and no legitimate pharmacy channel behind it. There is no lawful compounded price for AOD-9604 in 2026 because it isn’t on the bulks list and isn’t on the path that would put it there. If the goal is fat loss, the comparison that matters is against the FDA-approved GLP-1 route, where the higher price buys an actual medicine and an actual standard of care. As always, the regulatory picture is current as of this page’s update date and can change — but on today’s facts, the cheapest-looking AOD-9604 option is the one that costs the most where it counts.